Acquisition of one (1) Bio-Rad CFX Opus 96 Real-Time PCR System for the Laboratory of Receptor Biology and Gene Expression Branch (LRBGE), Center for Cancer Research (CCR), National Cancer Institute (NCI)

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH OLAO

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N98026Q00517

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Classification Code

6640

Additional Details
Set Aside

None

Place of Performance

Hercules, California, UNITED STATES

SourceSAM
The National Institutes of Health (NIH), Office of Logistics and Operations (OLAO), Hospital and Laboratory Support Division, has issued a presolicitation notice indicating its intent to acquire one (1) Bio-Rad CFX Opus 96 Real-Time PCR System. This procurement is specifically for the Laboratory of Receptor Biology and Gene Expression Branch (LRBGE) within the Center for Cancer Research (CCR) at the National Cancer Institute (NCI). The acquisition is classified under NAICS code 325414 (Biological Product [except Diagnostic] Manufacturing), with the place of performance identified as Hercules, California. Purpose and Scope: The primary objective of this procurement is to replace two obsolete and non-functional Bio-Rad CFX96 real-time PCR units that have been integral to the LRBGE’s research operations for approximately a decade. These legacy instruments are no longer supported by the manufacturer for repair or service, resulting in a significant reduction in the branch’s capacity for routine gene expression analysis, experimental quality control assays, and genomics workflows. The new Bio-Rad CFX Opus 96 Real-Time PCR System is intended to restore and enhance the laboratory’s real-time PCR capabilities, supporting multiple users and ongoing research programs. Key Requirements and Deliverables: The required system is a commercially available Bio-Rad CFX Opus 96 Real-Time PCR System, which must include: - A 96-well, 5-color plus FRET, network-connected real-time PCR detection platform - The CFX Opus 96 base unit - All necessary cables - CFX Maestro Software 2.3 for Windows The system must support comprehensive plate setup, data collection, statistical analysis, and graphical representation of results. Notably, the new platform offers improved block uniformity and multiplexing capabilities compared to the outdated units being replaced. Compatibility with existing software, established protocols, instrument parameters, and current consumables is essential to minimize disruption, avoid costly revalidation, and maintain workflow continuity. Contracting Entity and Contact Information: The contracting activity is managed by the NIH’s Office of Acquisition and Logistics Management (OALM), with the contracting office located at 6701 Rockledge Drive, Bethesda, MD 20817. The designated Contracting Officer is Mr. James Law, who can be reached via email at [email protected]. Procurement Type and Special Considerations: This acquisition is being conducted as a non-competitive, brand-name procurement under the authority of FAR Part 13—Simplified Acquisition Procedures, specifically Subpart 13.106-1(b)(1), which allows for solicitation from a single source. The total value of the procurement will not exceed the simplified acquisition threshold ($350,000). There are no set-aside requirements for this action. The procurement will include all applicable provisions and clauses in effect through Federal Acquisition Circular (FAC) 2026-01. Interested parties may submit capability statements, technical and cost proposals, and relevant business information by June 15, 2026, at 9:00 AM Eastern Time. All submissions must reference solicitation number 75N98026Q00517 and be sent electronically to the Contracting Officer. Only responses received by the deadline will be considered, and the Government reserves the right to proceed with a non-competitive award at its sole discretion. Summary: This presolicitation notice outlines NIH’s intent to restore and enhance critical real-time PCR capabilities for the LRBGE by acquiring a Bio-Rad CFX Opus 96 system. The procurement is justified on the basis of compatibility, continuity, and the need to avoid significant operational disruption. Contractors with the requisite capabilities are invited to respond, though the notice indicates a strong preference for the specified brand and model to ensure seamless integration with existing laboratory infrastructure.